Pharmacogenetics of etanercept: role of TNF-α gene polymorphisms in improving its efficacy

Bibliography

• Murdaca G, Colombo BM, Puppo F. Anti-TNF-alpha inhibitors: a new therapeutic approach for inflammatory immune-mediated diseases: an update upon efficacy and adverse events. Int J Immunopathol Pharmacol 2009;22(3):557-65
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Cagnati P, et al. Update upon efficacy and safety of TNF-alpha inhibitors. Expert Opin Drug Saf 2012;11(1):1-5
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events. Autoimmun Rev 2011;11(1):56-60
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. Adalimumab for the treatment of immune-mediated diseases: an update on old and recent indications. Drugs Today (Barc) 2011;47(4):277-88
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Barabino G, et al. Anti-tumor necrosis factor-alpha treatment with infliximab for disseminated granuloma annulare. Am J Clin Dermatol 2010;11(6):437-9
   PubMed Web of Science ®Google Scholar
• Puppo F, Murdaca G, Ghio M, Indiveri F. Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmun Rev 2005;4(8):537-41
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Puppo F. Selective TNF-alpha inhibitor-induced injection site reactions. Expert Opin Drug Saf 2013;12(2):187-93
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Puppo F. Use of leflunomide plus TNF-alpha inhibitors in rheumatoid arthritis. Expert Opin Drug Saf 2013;12(6):801-4
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Puppo F. Long term treatment of rheumatoid arthritis with adalimumab. Open Access Rheumatol Res Rev 2013;5:43-9
   PubMedGoogle Scholar
• Murdaca G, Spanò F, Puppo F. Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety. Expert Opin Drug Saf 2014;13(3):295-305
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Contatore M, et al. The potential use of TNF-alpha inhibitors in systemic sclerosis. Immunotherapy 2014;6(3):283-9
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Contatore M, et al. Efficacy and safety of etanercept in chronic immune-mediated disease. Expert Opin Drug Saf 2014;13(5):649-61
   PubMed Web of Science ®Google Scholar
• Carswell EA, Old LJ, Kassel RL, et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc Natl Acad Sci USA 1975;72:3666-70
   PubMed Web of Science ®Google Scholar
• Hehlgans T, Pfeer K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology 2005;115:1-20
   PubMed Web of Science ®Google Scholar
• Taylor PC. Antibody therapy for rheumatoid arthritis. Curr Opin Pharmacol 2003;3:323-8
   PubMed Web of Science ®Google Scholar
• Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents—a guide for GPs. Aust Fam Physician 2007;36:1035-8
   PubMed Web of Science ®Google Scholar
• Hochberg MC, Lebwohl MG, Plevy SE, et al. The benefit/risk profile of TNF-blocking agents: findings of a consensus panel. Semin Arthritis Rheum 2005;34:819-36
   PubMed Web of Science ®Google Scholar
• Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005. Ann Rheum Dis 2005;64(Suppl 4):iv2-14
   PubMedGoogle Scholar
• Gisondi P, Girolomoni G. Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev 2007;6:515-19
   PubMed Web of Science ®Google Scholar
• Kyle S, Chandler D, Griffiths CEM, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology 2005;44:390-7
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Contini P, Puppo F. Determination of lymphotoxin-alpha levels in patients with psoriatic arthritis undergoing etanercept treatment. J Interferon Cytokine Res 2012;32(6):277-9
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Puppo F. The role of Th17 lymphocytes in the autoimmune and chronic inflammatory diseases. Intern Emerg Med 2011;6(6):487-95
   PubMed Web of Science ®Google Scholar
• Chiang EY, Kolumam GA, Yu X, et al. Targeted depletion of lymphotoxin-alpha-expressing TH1 and TH17 cells inhibits autoimmune disease. Nat Med 2009;15(7):766-73
   PubMed Web of Science ®Google Scholar
• Takemura S, Braun A, Crowson C, et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001;167:1072-80
   PubMed Web of Science ®Google Scholar
• Bocchino M, Matarese A, Bellofiore B, et al. Performance of two commercial blood IFN-gamma release assays for the detection of Mycobacterium tuberculosis infection in patient candidates for anti-TNF-alpha treatment. Eur J Clin Microbiol Infect Dis 2008;27(10):907-13
   PubMed Web of Science ®Google Scholar
• Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003;48:1667-75
   PubMed Web of Science ®Google Scholar
• Hatemi G, Melikoglu M, Ozbakir F, et al. Quantiferon-TB Gold in tube assay for the screening of tuberculosis before and during treatment with tumor necrosis factor alpha antagonists. Arthritis Res Ther 2012;14(3):R147
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Cagnati P, Puppo F. Free radicals and endothelial dysfunction: potential positive effects of TNF-alpha inhibitors. Redox Rep 2013;18(3):95-9
   PubMed Web of Science ®Google Scholar
• Murdaca G, Spanò F, Miglino M, Puppo F. Effects of TNF-alpha inhibitors upon the mechanisms of action of VEGF. Immunotherapy 2013;5(2):113-15
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Murdaca G, Colombo BM, et al. Serum vascular endothelial growth factor in allergic rhinitis and systemic lupus erythematosus. Hum Immunol 2008;69(8):510-12
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Colombo BM, Murdaca G, De Amici M. Serum vascular endothelial growth factor and sublingual immunotherapy. Allergy 2008;63(7):945-6
   PubMed Web of Science ®Google Scholar
• Szekanecz Z, Kerekes G, Soltész P. Vascular effects of biologic agents in RA and spondyloarthropathies. Nat Rev Rheumatol 2009;5(12):677-84
   PubMed Web of Science ®Google Scholar
• Colombo BM, Cacciapaglia F, Puntoni M, et al. Traditional and non traditional risk factors in accelerated atherosclerosis in systemic lupus erythematosus: role of vascular endothelial growth factor (VEGATS Study). Autoimmun Rev 2009;8(4):309-15
   PubMed Web of Science ®Google Scholar
• Colombo BM, Murdaca G, Caiti M, et al. Intima-media thickness: a marker of accelerated atherosclerosis in women with systemic lupus erythematosus. Ann N Y Acad Sci 2007;1108:121-6
   PubMed Web of Science ®Google Scholar
• Murdaca G, Colombo BM, Cagnati P, et al. Endothelial dysfunction in rheumatic autoimmune diseases. Atherosclerosis 2012;224(2):309-17
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Watson KD, Silman AJ, Symmons DP. British Society for Rheumatology Biologics Register. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006;45(12):1558-65
   PubMed Web of Science ®Google Scholar
• Kooloos WM, de Jong DJ, Huizinga TW, Guchelaar HJ. Potential role of pharmacogenetics in anti-TNF treatment of rheumatoid arthritis and Crohn’s disease. Drug Discov Today 2007;12(3-4):125-31
   PubMed Web of Science ®Google Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, et al. For the PREMIER Investigators. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81
   PubMed Web of Science ®Google Scholar
• Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004;50:1051-65
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 2006;130:323-33
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002;359:1541-9
   PubMed Web of Science ®Google Scholar
• Emery P, Dörner T. Optimising treatment in rheumatoid arthritis: a review of potential biological markers of response. Ann Rheum Dis 2011;70(12):2063-70
   PubMed Web of Science ®Google Scholar
• Louis E, Franchimont D, Piron A, et al. Tumor necrosis factor (TNF) gene polymorphism influences TNF-alpha production in lipopolysaccharide (LPS)-stimulated whole blood cell culture in healthy humans. Clin Exp Immunol 1998;113:401-6
   PubMed Web of Science ®Google Scholar
• Guis S, Balandraud N, Bouvenot J, et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. Arthritis Rheum 2007;57(8):1426-30
   PubMed Web of Science ®Google Scholar
• Padyukov L, Lampa J, Heimbürger M, et al. Genetic markers for the efficacy of tumor necrosis factor blocking therapy in rheumatoid arthritis. Ann Rheum Dis 2003;62:526-9
   PubMed Web of Science ®Google Scholar
• Seitz M, Wirthmüller U, Möller B, Villiger PM. The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNF alpha-blockers in rheumatoid arthritis and spondyloarthritis patients. Rheumatology (Oxford) 2007;46(1):93-6
   PubMed Web of Science ®Google Scholar
• Maxwell JR, Potter C, Hyrich KL, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008;17(22):3532-8
   PubMed Web of Science ®Google Scholar
• Schmeling H, Horneff G. Tumour necrosis factor alpha promoter polymorphisms and etanercept therapy in juvenile idiopathic arthritis. Rheumatol Int 2007;27(4):383-6
   PubMed Web of Science ®Google Scholar
• Stojanović S, Jevtović-Stoimenov T, Stanković A, et al. [Association of TNF-alpha polymorphism (-308 A/G) with high activity of rheumatoid arthritis and therapy response to Etanercept]. Srp Arh Celok Lek 2011;139(11-12):784-9
   PubMed Web of Science ®Google Scholar
• Marotte H, Arnaud B, Diasparra J, et al. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. Arthritis Rheum 2008;58(5):1258-63
   PubMed Web of Science ®Google Scholar
• Kang CP, Lee KW, Yoo DH, et al. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in. rheumatoid arthritis. Rheumatology 2005;44:547-52
   PubMed Web of Science ®Google Scholar
• Schotte H, Schlüter B, Drynda S, et al. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. Ann Rheum Dis 2005;64(4):575-81
   PubMed Web of Science ®Google Scholar
• Murdaca G, Gulli R, Spanò F, et al. TNF-α Gene Polymorphisms: Association with Disease Susceptibility and Response to Anti-TNF-α Treatment in Psoriatic Arthritis. J Invest Dermatol 2014;134(10):2503-9
   PubMed Web of Science ®Google Scholar
• Morales-Lara MJ, Cañete JD, Torres-Moreno D, et al. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 2012;79(6):591-6
   PubMed Web of Science ®Google Scholar
• Pierik M, Vermeire S, Steen KV, et al. Tumour necrosis factor-a receptor 1 and 2 polymorphisms in inflammatory bowel disease and their association with response to infliximab. Aliment Pharmacol Ther 2004;20:303-10
   PubMed Web of Science ®Google Scholar
• Louis EJ, Watier HE, Schreiber S, et al. Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn’s disease: a subanalysis of the ACCENT I study. Pharmacogenet Genomics 2006;16:911-14
   PubMed Web of Science ®Google Scholar
• Ho P, Bruce IN, Silman A, et al. Evidence forcommongenetic control in pathways of inflammation for Crohn’s disease and psoriatic arthritis. Arthritis Rheum 2005;52:3596-602
   PubMed Web of Science ®Google Scholar
• Nimmerjahn F, Ravetch JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8(1):34-47
   PubMed Web of Science ®Google Scholar
• Bruhns P, Iannascoli B, England P, et al. Specificity and affinity of human Fc gamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009;113(16):3716-25
   PubMed Web of Science ®Google Scholar
• van Sorge NM, van der Pol WL, van deWinkel JG. FcgammaR polymorphisms: implications for function, disease susceptibility and immunotherapy. Tissue Antigens 2003;61(3):189-202
   PubMed Web of Science ®Google Scholar
• Canete JD, Suarez B, Hernandez MV, et al. Influence of variants of Fcgamma receptors IIA and IIIA on the American College of Rheumatology and European League Against Rheumatism responses to anti–tumor necrosis alpha therapy in rheumatoid arthritis. Ann Rheum Dis 2009;68(10):1547-52
   PubMed Web of Science ®Google Scholar
• Tutuncu Z, Kavanaugh A, Zvaifler N, et al. Fcgamma receptor type IIIA polymorphisms influence treatment outcomes in patients with inflammatory arthritis treated with tumor necrosis factor alpha–blocking agents. Arthritis Rheum 2005;52(9):2693-6
   PubMed Web of Science ®Google Scholar
• Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn’s disease. Aliment Pharmacol Ther 2004;19(5):511-19
   PubMed Web of Science ®Google Scholar
• Julià M, Guilabert A, Lozano F, et al. The role of Fcgamma receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study. JAMA Dermatol 2013;149(9):1033-9
   PubMed Web of Science ®Google Scholar
• Fantuzzi F, Del Giglio M, Gisondi P, Girolomoni G. Targeting tumor necrosis factor alpha in psoriasis and psoriatic arthritis. Expert Opin Ther Targets 2008;12(9):1085-96
   PubMed Web of Science ®Google Scholar
• Strange A, Capon F, Spencer CC, et al. A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nat Genet 2010;42(11):985-90
   PubMed Web of Science ®Google Scholar
• Boyton RJ, Altmann DM. Natural killer cells, killer immunoglobulin-like receptors and human leucocyte antigen class I in disease. Clin Exp Immunol 2007;149:1-8
   PubMed Web of Science ®Google Scholar
• Ryan C, Kelleher J, Fagan MF, et al. Genetic markers of treatment response to tumour necrosis factor-alpha inhibitors in the treatment of psoriasis. Clin Exp Dermatol 2014;39(4):519-24
   PubMed Web of Science ®Google Scholar
• Criswell LA, Lum RF, Turner KN, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. Arthritis Rheum 2004;50:2750-6
   PubMed Web of Science ®Google Scholar
• Potter C, Cordell HJ, Barton A, et al. Association between anti tumour necrosis factor treatment response and genetic variants within the TLR and NF{kappa}B signalling pathways. Ann Rheum Dis 2010;69(7):1315-20
   PubMed Web of Science ®Google Scholar
• Jančić I, Arsenović-Ranin N, Sefik-Bukilica M, et al. -174G/C interleukin-6 gene promoter polymorphism predicts therapeutic response to etanercept in rheumatoid arthritis. Rheumatol Int 2013;33(6):1481-6
   PubMed Web of Science ®Google Scholar
• Tejasvi T, Stuart PE, Chandran V, et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol 2012;132(3 Pt 1):593-600
   PubMed Web of Science ®Google Scholar
• Tan RJ, Gibbons LJ, Potter C, et al. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. Ann Rheum Dis 2010;69(6):1029-35
   PubMed Web of Science ®Google Scholar
• Cui J, Saevarsdottir S, Thomson B, et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2010;62(7):1849-61
   PubMed Web of Science ®Google Scholar